All companies › BOLT

BOLT · Bolt Biotherapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells9
Research cases0
Last filing2026-09-18

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-16 — Quinn William P. · sold 1,889 @ $3.77 2026-09-16 — Nemec Sarah · sold 843 @ $3.77 2026-09-16 — Yonehiro Grant · sold 1,417 @ $3.77 2026-09-17 — Quinn William P. · sold 6,545 @ $3.32 2026-09-17 — Nemec Sarah · sold 2,922 @ $3.32 2026-09-17 — Yonehiro Grant · sold 4,909 @ $3.32 2026-09-18 — Quinn William P. · sold 9,132 @ $3.24 2026-09-18 — Nemec Sarah · sold 4,077 @ $3.24 2026-09-18 — Yonehiro Grant · sold 6,850 @ $3.24
2026-09-162026-09-18

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Quinn William P. President, CEO and CFO, Director
Nemec Sarah Senior VP, Finance and PAO
Yonehiro Grant Chief Operating Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $BOLT is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-18', 'insider_name': 'Quinn William P.', 'insider_title': 'President, CEO and CFO, Director', 'transaction_type': 'Open-market sell', 'shares': 9132.0, 'price': 3.24, 'value': 29587.68, 'is_buy': False}, {'transaction_date': '2026-09-18', 'insider_name': 'Nemec Sarah', 'insider_title': 'Senior VP, Finance and PAO', 'transaction_type': 'Open-market sell', 'shares': 4077.0, 'price': 3.24, 'value': 13209.48, 'is_buy': False}, {'transaction_date': '2026-09-18', 'insider_name': 'Yonehiro Grant', 'insider_title': 'Chief Operating Officer', 'transaction_type': 'Open-market sell', 'shares': 6850.0, 'price': 3.24, 'value': 22194.0, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Quinn William P.', 'insider_title': 'President, CEO and CFO, Director', 'transaction_type': 'Open-market sell', 'shares': 6545.0, 'price': 3.32, 'value': 21729.4, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Nemec Sarah', 'insider_title': 'Senior VP, Finance and PAO', 'transaction_type': 'Open-market sell', 'shares': 2922.0, 'price': 3.32, 'value': 9701.04, 'is_buy': False}, {'transaction_date': '2026-09-17', 'insider_name': 'Yonehiro Grant', 'insider_title': 'Chief Operating Officer', 'transaction_type': 'Open-market sell', 'shares': 4909.0, 'price': 3.32, 'value': 16297.88, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Quinn William P.', 'insider_title': 'President, CEO and CFO, Director', 'transaction_type': 'Open-market sell', 'shares': 1889.0, 'price': 3.77, 'value': 7121.53, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Nemec Sarah', 'insider_title': 'Senior VP, Finance and PAO', 'transaction_type': 'Open-market sell', 'shares': 843.0, 'price': 3.77, 'value': 3178.11, 'is_buy': False}, {'transaction_date': '2026-09-16', 'insider_name': 'Yonehiro Grant', 'insider_title': 'Chief Operating Officer', 'transaction_type': 'Open-market sell', 'shares': 1417.0, 'price': 3.77, 'value': 5342.09, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for BOLT today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.